01. Introduction

A case I recently handled is quite typical. The client is a company engaged in the research, development and manufacture of physical AI products, mainly developing and producing high-tech product equipment used in certain special scenarios, with products already exported to multiple countries and regions including the United States, Canada and the European Union. At present, the company's IPO has entered the coaching stage; intermediaries such as the securities firm, law firm and accounting firm have all begun providing services, and all work is proceeding as planned. However, a formal investigation notice from the U.S. Consumer Product Safety Commission (hereinafter "CPSC") suddenly put the entire listing team on edge—a flagship product had been complained about by consumers due to a safety hazard of chip overheating and catching fire, and the CPSC required the company to make a formal response within a specified period.

The client's anxiety is focused and specific:

Does the CPSC recall investigation constitute a substantive obstacle to the IPO? Should temporary information disclosure obligations be performed with the stock exchange immediately? How can the listing process be advanced while responding to the U.S. regulatory investigation?

These questions are becoming a real dilemma faced by an increasing number of Chinese companies planning to list. In 2025, the U.S. CPSC issued a total of 422 recall notices, up 38.4% year on year, of which 315 involved products from China, accounting for 74.6% of the CPSC's total recalls and involving approximately USD 11.32 billion [1]. In the first quarter of 2026, the CPSC issued a total of 142 recall notices, up 40.6% year on year, of which 120 involved products from China, an increase of 73.9% year on year, accounting for 84.5% of the CPSC's total recalls and involving approximately USD 2.08 billion [1]. It can be foreseen that encountering a CPSC investigation at a critical stage of an IPO is no longer a low-probability event.

This article intends to start from the legal framework of the CPSC recall system, combine it with practical cases in recent years, systematically analyze the multi-dimensional impact of recall investigations on the IPOs of companies planning to list, and put forward practical suggestions for lawyers.

(1) The CPSC's Statutory Duties and Scope of Jurisdiction

The CPSC is an independent federal regulatory agency of the United States, established in 1972. It exercises its powers under the Consumer Product Safety Act (hereinafter "CPSA") and reports directly to Congress and the President. The CPSC is responsible for safety monitoring of more than 15,000 types of consumer products used in homes, sports, recreation and schools. Most goods exported from China to the United States fall within the CPSC's jurisdiction.

The CPSC's main functions include: conducting continuous supervision and compliance inspections of the consumer product market; carrying out research and investigations into potential hazards related to consumer products; and formulating and improving safety regulatory norms for product design, production, sales and distribution. In addition, the CPSC may apply to U.S. federal district courts for injunctions and civil penalties, and may refer cases to the U.S. Department of Justice for criminal liability.

(2) The 24-Hour Reporting Obligation and the 10-Working-Day Investigation Period

In most cases, the CPSC's involvement in a product recall begins with a party subject to the reporting obligation fulfilling its "reporting obligation" to the CPSC regarding a product defect. Parties subject to the reporting obligation include manufacturers, importers, distributors, retailers, brand owners, etc. Sections 15, 37 and 102 of the CPSA set out the specific requirements for fulfilling the reporting obligation in different circumstances [2].

The core rule is contained in Section 15(b) of the CPSA (15 U.S.C. § 2064(b)): when a "reportable event" occurs with respect to a product in commerce, the party subject to the reporting obligation shall report to the CPSC "within 24 hours" [2]. A so-called "reportable event" means information obtained by the company that reasonably supports the conclusion that the product contains a defect which could create a substantial risk of injury, or which creates an unreasonable risk of serious injury or death. Even if the company's own investigation is still ongoing, as long as it has obtained information that needs to be reported, it should report to the CPSC within 24 hours.

The CPSC's official guidance further clarifies that a company's investigation to determine whether a reportable event exists should not exceed 10 working days, unless the company can demonstrate that a longer period is reasonable in the specific circumstances. In the absence of such circumstances, the CPSC will presume that by the end of the 10 working days the company has received and considered all information it could have obtained in a reasonable, expeditious and diligent investigation [2].

The CPSA applies not only to corporate entities; directors, senior officers or agents who "knowingly and willfully authorize, order or cause" a late report may also be held liable (15 U.S.C. § 2070(b)), with a maximum penalty of 5 years' imprisonment and a fine [2]. The CPSC's penalties for violating the reporting obligation are extremely severe—for each day of delayed reporting, the maximum fine can reach USD 120,000, and the maximum civil penalty for a related series of violations is USD 17.15 million [2].

(3) Investigation Procedure and Preliminary Determination

After receiving a report, the CPSC generally takes several months to test the product and issue a Preliminary Determination (hereinafter "PD"). During the investigation, the CPSC usually sends the company a questionnaire list requiring submission of comprehensive materials such as product design, production, sales, customer complaints and certification reports. If the CPSC makes a PD finding that the product has a safety defect requiring recall, the PD notice will require the company under investigation to reply within 10 working days as to whether it agrees to the recall. In practice, the vast majority of companies under investigation, under pressure from the CPSC, agree to a recall before the CPSC even issues a PD [3].

(4) Fast-track Recall Program

To address the problem of lengthy investigation cycles, the CPSC created the Fast-track Recall Program. Within 20 working days after fulfilling the reporting obligation, a company may apply to the CPSC for application of the fast-track recall procedure. Applying this procedure can substantially shorten the recall cycle and reduce recall costs, and is an important strategic option for companies responding to CPSC investigations [3].

In the CPSC's enforcement history, the case of Gree's U.S. subsidiary is a landmark. This was not only the first case in the United States in which corporate executives were held criminally liable and sentenced to imprisonment for failing to fulfill the reporting obligation under the CPSA, but also sent a clear signal to all companies exporting to the United States [4][5][6].

The product involved was a household dehumidifier manufactured by Gree Electric Appliances, Inc. of Zhuhai and imported and sold by its U.S. subsidiary Gree USA, Inc. Since 2012, senior executives of Gree USA had successively received complaints and reports of product fires and safety defects. As early as September 2012, two senior executives already knew that the dehumidifiers posed a fire risk. However, despite knowing of the safety hazard, the two not only failed to report to the CPSC but continued selling the defective products to U.S. retailers, selling 285,596 defective dehumidifiers in the first four months of 2013 alone [4][6]. The company did not first report the matter to the CPSC until March 2013—by which time at least six months had passed since it first became aware. Moreover, the first report did not truthfully disclose all information about the product defects and hazards [6].

The defective dehumidifiers were ultimately confirmed to be involved in more than 450 fires, causing approximately USD 19 million in property damage. Four deaths or serious injuries were linked to the product [4][6].

The case did not stop at corporate liability. In March 2019, the U.S. Department of Justice brought criminal charges against two core executives of Gree USA—Chief Executive Officer Charley Loh (67) and Chief Administrative Officer Simon Chu (70). In November 2023, a federal jury convicted both on two counts: conspiracy to defraud the CPSC and failure to furnish required information in violation of the CPSA. On June 16, 2025, the U.S. District Court for the Central District of California handed down its judgment (case number: UNITED STATES v. SIMON CHU and CHARLEY LOH): Charley Loh was sentenced to 40 months' federal imprisonment, a fine of USD 12,000 and three years' supervised release; Simon Chu was sentenced to 38 months' federal imprisonment, a fine of USD 5,000 and three years' supervised release [4][5][6]. In sentencing, the judge noted that the two executives "undoubtedly placed their own financial interests above consumer safety" [5].

At the corporate level, Gree USA was sentenced in April 2023 to a criminal fine of USD 500,000. Gree Zhuhai, Gree Hong Kong and Gree USA reached a criminal settlement agreement with the U.S. Department of Justice in 2021, under which the three parties jointly bore a criminal fine of USD 91 million (less the USD 15.45 million in civil penalties already paid) and agreed to provide compensation to uncompensated fire victims [4][6][8]. The U.S. Department of Justice noted that this was the first corporate criminal enforcement action brought since the enactment of the CPSA [6].

The Gree case marks a major shift in U.S. product safety regulation—criminal liability has extended from companies to individual executives. For Chinese companies planning to list, the warning of this case is particularly prominent: once the reporting obligation is triggered and not fulfilled in a timely manner, the company may face huge fines, and individual executives may face imprisonment.

04. The Multi-dimensional Impact of CPSC Recall Investigations on the IPOs of Companies Planning to List

(1) The Information Disclosure Dimension: Does It Constitute a "Major Event"?

This is the most direct path of impact of a recall investigation on an IPO. Under the Securities Law and the relevant rules of the stock exchanges, issuers have a continuous information disclosure obligation during the IPO process. All information that has a material impact on investors' value judgments and investment decisions shall be disclosed.

From the review practice of the stock exchanges, product recall issues have entered the regulatory spotlight. IPO companies have been required in review inquiries to explain: what were the reasons for the product recall; whether the defective products caused accidents or disputes; whether the competent authorities took regulatory measures against the issuer; and how the above matters were investigated and rectified [11]. For companies planning to list, the judgment of "materiality" of a CPSC investigation needs to consider multiple factors: whether the product involved is a core product or main source of revenue, the scope and scale of the recall, whether it caused personal injury or property damage, whether criminal liability risk is involved, etc.

(2) The Financial Dimension: Direct Losses and Contingent Liabilities

The financial impact of a recall is multi-layered. The recall itself involves direct costs such as refunds, replacements, logistics and after-sales service, and may also trigger inventory impairment. If the recall event occurs during the reporting period or after the reporting period but before the prospectus is disclosed, the company needs to assess whether warranty liabilities or contingent liabilities need to be accrued.

Taking Anker Innovations as an example, in 2025 it recalled more than 2.38 million power banks worldwide [9][10]. The CPSC issued recall announcements in June and September 2025 respectively, covering a cumulative total of approximately 2.352 million power banks; the CPSC received 33 reports of fire and explosion, including 4 people with minor burns and 1 person with serious property damage [9]. The replacement, logistics, and after-sales compensation advances arising from the global product recall amounted to RMB 392 million [9]. Affected by the recall incident, the net cash flow from operating activities in 2025 was RMB 481 million, a year-on-year decline of 82.5% [9]. In its new version of the prospectus, Anker Innovations recorded the potential compensation cap of RMB 172 million as a contingent liability, and at the same time added a product quality warranty liability of RMB 104 million [9][10].

(III) Compliance and internal control dimension: the regulator's deeper doubts

Recall incidents often reflect deep-seated deficiencies in a company's quality management system and supply chain control. Regulators focus not only on the recall incident itself, but more on the internal control problems exposed by the recall: whether there are loopholes in the quality management system; whether supply chain control is adequate; whether pre-delivery testing is sufficient; and whether the feedback mechanism for consumer complaints is effective.

If a company cannot provide convincing explanations and rectification measures to the regulator on the above issues, the IPO review process is likely to be seriously affected. In addition, if a company fails to perform its reporting obligations in a timely manner or deliberately conceals product defects, it may also face criminal liability risk—the Gree case has already proven that this is not alarmist talk.

(IV) Reputation and investor confidence dimension

The CPSC's recall announcements are published simultaneously through its official website and cooperating media. Once made public, investors, customers, and partners will all learn of them. The market will judge accordingly: is this recall an isolated incident, or an exposure of the company's systemic quality problems? Once investor confidence is damaged, both the IPO issue pricing and the scale of fundraising may be adversely affected.

05. Lessons from practical cases

(I) Anker Innovations: a swift second IPO filing after the recall

In 2025, an upstream battery cell supplier of Anker Innovations (Anpuris Wuxi Co., Ltd.) privately changed core materials during production, causing safety hazards in some batches of its power banks. For this reason, Anker Innovations recalled more than 2.38 million power banks cumulatively in the global market [9][10].

The recall had a significant financial impact on Anker Innovations. Its first Hong Kong stock prospectus lapsed on June 2, 2026, and the company swiftly filed a second time the next day [9][10]. The new version of the prospectus did three things: it disclosed in detail the cause of the incident—that it was caused by an individual upstream battery cell supplier privately replacing raw materials; it disclosed a full-chain rectification plan—terminating cooperation with the supplier involved, building a dual-supplier system for battery cells, reducing the capacity share of the top five contract manufacturers from 82% to 73%, and adding 22 alternative manufacturers; and it simultaneously disclosed the progress of relevant regulatory investigations by the U.S. CPSC and Japan's Ministry of Health, Labour and Welfare, and recorded the potential compensation cap of RMB 172 million as a contingent liability [9][10].

The Anker Innovations case shows that a recall is not necessarily the end of an IPO; the key lies in full disclosure, active rectification, and candid response.

(II) Jengeng Medical: recall compounded by internal control problems, both IPOs failed

Jengeng Medical focuses on the field of organ transplant medical devices, and its core products come from the acquisition of the U.S. company LSI. After the acquisition, two product quality risk incidents occurred and product recalls were implemented. On January 30, 2020, its subsidiary ORS conducted a voluntary recall because 6 batches of infusion circuit tubing sets had a risk of liquid leakage [11][12]. From late 2016 to early 2017, another 4 batches of organ preservation solution were recalled due to contamination [11][12]. In response to the above recalls, the company made asset impairment provisions of RMB 3.5285 million [11][12].

Jengeng Medical filed twice for a STAR Market IPO, in May 2020 and November 2022 respectively. The first time, after 4 rounds of inquiries, it voluntarily withdrew its application on the eve of the listing review meeting. The second time, in April 2024, because the company and its sponsor withdrew the issuance and listing application, the Shanghai Stock Exchange terminated its issuance and listing review [11][12].

Jengeng Medical's two failed IPOs—although product recalls were not the only reason, they produced a cumulative effect when combined with other problems: more than 70% of the company's revenue came from overseas subsidiaries, and its core technology and R&D team largely depended on overseas entities; its core products were produced through outsourcing, facing relatively large quality control risks; in addition, the company had illegally used raised funds to repay loans [11][12]. The Jengeng Medical case shows that a recall itself may not constitute a "fatal wound" to an IPO, but a recall compounded by other compliance problems will cause regulators to seriously question the company's overall governance capability and going-concern ability.

06. Practical suggestions for lawyers

(I) Immediately activate an internal response mechanism

After receiving a CPSC investigation notice, a company should, at the first opportunity, establish a cross-departmental response team whose members should include the heads of key departments such as legal, quality, production, R&D, and finance. The primary task is to assess: whether the product defect actually exists; how serious the defect is; and whether the 24-hour reporting obligation has already been triggered. A company's investigation to determine whether a reportable matter exists should not exceed 10 working days [2].

(II) Cautiously handle communications with the CPSC

When responding to a CPSC investigation, companies are advised to follow the three principles of "honest and prudent, direct, limited and necessary" [3]. "Honest and prudent" means not lying, speaking on the basis of facts, and not deliberately concealing or falsifying facts; "direct" means directly answering the CPSC's questions, answering exactly what is asked; "limited and necessary" means that the materials or answers submitted must not "branch out" and should avoid triggering a series of further questions from the CPSC [3]. One of the lessons of the Gree case is that the two executives not only reported late, but also concealed all information about the product defects and hazards in their first report—this conduct directly led to criminal charges of conspiring to defraud the CPSC [4][6].

(III) Assess the recall strategy

If, after assessment, it is confirmed that the product defect actually exists, companies are advised to proactively initiate a recall and to assess whether the fast-track recall procedure applies [3]. The earlier the action, the more the initiative can be grasped. The recall method can be negotiated with the CPSC; common recall methods include refunds, replacements, adding warning labels, and replacing instructions for use [3]. I once handled a recall case in which, after negotiation, the CPSC ultimately required only that the recalling company provide consumers with a piece of gauze to grind down a protrusion on the bottom of an appliance that could stab the user's palm. This fully demonstrates that a reasonable negotiation strategy can significantly reduce recall costs.

(IV) Simultaneously activate an IPO response plan

Companies should simultaneously activate an IPO response plan, including but not limited to: assessing whether the CPSC investigation constitutes a material matter requiring disclosure; if disclosure is required, immediately preparing supplementary disclosure content for the prospectus; communicating with the sponsor and auditors to assess the impact on financial data—whether provisions need to be made, whether financial forecasts need to be adjusted, and whether contingent liabilities need to be additionally disclosed; and preparing in advance a plan for responding to exchange inquiries.

CPSC recall investigations involve multiple professional fields such as U.S. law, Chinese law, product quality, and IPO compliance, and are highly interdisciplinary. The Gree case, from the corporate fine to the executives' sentencing, lasted nearly ten years—professional legal support concerns not only response efficiency, but also the fate of the company and individual executives.

Conclusion

A CPSC recall investigation is not equivalent to a "death sentence" for an IPO. The practice of Anker Innovations shows that actively, professionally, and transparently responding to a recall incident may instead demonstrate to regulators and investors the company's compliance capability and governance level. The Jengeng Medical case, by contrast, reminds us that if a recall is compounded by problems such as internal control deficiencies, it may become the last straw that breaks the IPO's back.

The case of Gree Electric's U.S. subsidiary provides the deepest warning: the product safety reporting obligation is not an empty phrase, and the consequences of late reporting and concealment are not only civil fines, but may also be the personal criminal liability of executives. For companies planning to list, a CPSC investigation is not only a test of product safety compliance capability, but also a "stress test" of the company's overall governance capability.

The recall incident itself is not frightening; what is frightening is improper response, false disclosure, and concealment without reporting. In today's increasingly stringent CPSC enforcement, compliance is not a cost, but a passport for companies to enter the capital market.

Questions and answers

What is the CPSC's 24-hour reporting obligation under the CPSA?

Under Section 15(b) of the CPSA, when a reportable event occurs—such as information that a product contains a defect creating a substantial risk of injury—the manufacturer, importer, distributor, or retailer must report to the CPSC within 24 hours, even if its own investigation is ongoing.

How did the Gree case affect executive liability for late reporting to the CPSC?

In the Gree case, two executives were criminally convicted for conspiracy to defraud the CPSC and failure to furnish required information. They received federal prison sentences of 40 and 38 months, respectively, demonstrating that individuals can face imprisonment for knowingly violating CPSA reporting obligations.

What financial impacts should a company consider from a CPSC recall during an IPO?

A recall can cause direct costs like refunds and logistics, inventory impairment, and contingent liabilities. For example, Anker Innovations recorded RMB 392 million in recall costs, a RMB 172 million contingent liability, and a RMB 104 million warranty liability, affecting its cash flow and prospectus disclosures.

What are the practical steps for responding to a CPSC investigation during an IPO?

Companies should immediately form a cross-departmental response team, assess whether the 24-hour reporting obligation is triggered, communicate with the CPSC honestly and directly, consider the fast-track recall program, and simultaneously prepare IPO disclosures and exchange inquiry responses with professional legal counsel.

Laws and cases cited

Laws

  • Consumer Product Safety Act
  • 15 U.S.C. § 2070(b)
  • Securities Law

Cases

  • UNITED STATES v. SIMON CHU and CHARLEY LOH

References

  1. CPSC recall statistics. Publicly released data on the official website of the U.S. Consumer Product Safety Commission (CPSC) (2025 and the first quarter of 2026).
  2. Consumer Product Safety Act (CPSA), 15 U.S.C. §§ 2051-2089, in particular Section 15(b) (15 U.S.C. § 2064(b)), Section 37, Section 102 and Section 27(b) (15 U.S.C. § 2070(b)); CPSC official guidance on the 10-working-day investigation period and civil penalty standards.
  3. CPSC Fast-track Recall Program provisions and practical operation guidance.
  4. United States v. Simon Chu and Charley Loh, criminal case in the U.S. District Court for the Central District of California; for reports on the judgment, see the Concord & Sage law firm website article "The First U.S. Criminal Sentencing of Executives for Product Safety 'Late Reporting': Compliance Implications for Chinese-Funded Enterprises" and related judicial documents.
  5. China Business Journal / National Business Daily. Reports on the sentencing of executives in the Gree dehumidifier case (June 2025).
  6. CNR. Gree dehumidifiers alleged to have caused fires in the U.S.; agrees to pay USD 154.5 million fine (2016); U.S. Department of Justice announcement on the Gree criminal settlement agreement (2021); National Business Daily follow-up reports on the Gree U.S. subsidiary case.
  7. Concord & Sage law firm. The First U.S. Criminal Sentencing of Executives for Product Safety 'Late Reporting': Compliance Implications for Chinese-Funded Enterprises.
  8. Lanjinger / China Business Journal. Reports on the Gree dehumidifier recall case and CPSC announcements.
  9. Hexun / Sina. Reports on Anker Innovations' global recall of more than 2.38 million power banks; disclosure content of Anker Innovations' new version of the Hong Kong stock prospectus.
  10. Lanjinger. Reports on Anker Innovations' CPSC recall announcement and accident statistics.
  11. Economic Information Daily. Jengeng Medical IPO: two product recalls due to quality problems, once illegally used raised funds to repay debts (September 26, 2023).
  12. Baijiahao/Yicaixin. Reports on Jianggeng Medical's two STAR Market IPO filings and withdrawals; Shanghai Stock Exchange issuance and listing review information.